3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
26
Lymphoma, Large B-Cell, Diffuse
24
Burkitt Lymphoma
19
Lymphoma, Follicular
15
Lymphoma
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Neoplasms
8
Lymphoma, Non-Hodgkin
8
Lymphoma, B-Cell
6
Recurrence
5
Prostatic Neoplasms, Castration-Resistant
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, B-Cell, Marginal Zone
5
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Biphenotypic, Acute
4
Ovarian Neoplasms
3
Lymphoproliferative Disorders
3
Lymphoma, T-Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Prostate Cancer Metastatic
2
Plasmablastic Lymphoma
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer
2
Melanoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell, Cutaneous
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Enteropathy-Associated T-Cell Lymphoma
2
Interventions
darolutamide
2
Docetaxel
2
Androgen Antagonists
2
niraparib
1
Prednisone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
×
Prednisone
×
90 days
×
Clear all
NCT06392841
2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2
Withdrawn